;)
Real-World Evidence: Regulatory Acceptance Has Arrived – Quietly
The FDA released final guidance on real-world data in July 2024. The EMA expanded DARWIN EU to 30 partners covering 180 million patients across 16 European Countries (EMA, 2025). Japan’s PMDA now accepts Real-World Evidence (RWE) for external control arms in orphan drugs, with multiple recent approvals using registry- or database-based external controls where randomized trials were not feasible (Asano et al., 2025). Taken together, these moves suggest that a regulatory inflection point for RWE has likely already occurred, even if operational practice is still catching up (FDA, 2025; Castor EDC, 2025).
What’s notable is how little industry chatter followed.
Real-world evidence has transitioned from speculative future technology to documented regulatory decision-making tool, with formal frameworks now in place across major agencies (FDA, 2018, EMA, 2025). The FDA’s published case studies show RWE now supporting approval decisions, labeling changes, and risk-benefit reassessments across diverse therapeutic areas from rare genetic disorders to oncology (Purpura et al., 2022, FDA, 2025). These case examples typically describe the underlying real-world data source, the study design (for example, external control cohorts or observational effectiveness studies), and how the resulting RWE contributed to the overall benefit–risk assessment or labeling language (Purpura et al., 2022). Yet many sponsors continue to treat RWE as supplementary rather than foundational to their development strategy.
Regulators have begun to articulate a consistent acceptance threshold: RWE qualifies as substantial evidence when data provenance is transparent, collection is systematic, and validation demonstrates fidelity to randomized controlled trial endpoints (FDA, 2018,2024, EMA, 2025). In other words, real-world data must be curated and processed with the same rigor applied to prospective trials, including prespecified protocols, quality management, and traceable audit trails (Castor EDC, 2025). Extracting observational data from EHRs and declaring it “real-world evidence” doesn’t meet the standard; curating it into regulatory-grade datasets does (Castor EDC, 2025). This is presented in Table 1 below:
Table 1: Distinguishing Real‑World Data (RWD) from Real‑World Evidence (RWE) for Regulatory Decision-Making
| Term | Description |
| Real-world data (RWD) | Routinely collected data from clinical practice (for example, electronic health records, claims, registries, pharmacy data, or disease registries). These datasets are often heterogeneous, may contain missing or miscoded fields, and are not originally generated to answer a specific regulatory question. |
| Real-world evidence (RWE) | Analyzed, quality-assured results derived from RWD to answer a predefined clinical or regulatory question (for example, effectiveness, safety, or external control comparisons). RWE requires a fit-for-purpose study design, clear definitions of exposures and outcomes, and appropriate methods to control bias and confounding. |
| RWD – regulatory relevance | On its own, RWD is usually not sufficient for regulatory decision-making because it lacks predefined protocol, outcome definitions, and quality controls aligned with regulatory standards. |
| RWE – regulatory relevance | When generated under a robust protocol with transparent methods, validation, and quality management, RWE can support, and in some cases contribute to, substantial evidence in regulatory evaluations (for example, external control arms, label expansions, or post-authorization safety studies). |
Where is adoption stalling?
Clinical trial mentality persists. The pharma industry’s operational and cultural infrastructure remains designed around prospective RCT logic: predefined protocols, prespecified analyses, and protocol-driven data collection. RWE requires a fundamentally different mental model: adaptive case definitions, exploratory analyses performed transparently with appropriate adjustment, iterative validation against clinical outcomes and closer collaboration between clinical, biostatistics, epidemiology, and data science teams.
- Analytical capability gaps. Extracting RWE at scale requires infrastructure—data partnerships, causal inference expertise, population health informatics, integration with electronic health record systems. Mid-size sponsors often lack this in-house, making RWE dependent on external CRO/CDMO partnerships. Cost and schedule trade-offs often make traditional trials seem more feasible, although this calculus is beginning to shift as more powerful data platforms and AI-enabled abstraction are deployed alongside clinical trials (Castor EDC, 2025)
- Liability and data governance. Managing patient consent, ensuring data sovereignty, navigating cross-border regulatory frameworks for multi-country RWE systems introduces legal complexity that has slowed adoption despite technical feasibility.
The Opportunity
Companies beginning RWE programs now are structuring them as parallel evidence streams during Phase II and Phase III. Rather than replacing prospective trials, they’re generating supporting evidence for regulatory discussions, pricing, and HTA submissions. The economic case for RWE strengthens when evidence supports multiple regulatory and commercial endpoints simultaneously —for example, when a single, well-designed RWE program can inform label discussions, payer negotiations, and post-approval safety commitments.
The regulatory shift toward accepting high-quality RWE is well underway; broader operational adoption is likely to depend on clearer, repeatable business cases for RWE deployment within development portfolios.
References
Asano, J., Sugano, H., Murakami, H., Noguchi, A., Ando, Y., & Uyama, Y. (2025). PMDA perspective on use of real-world data and real-world evidence as an external control: Recent examples and considerations. Clinical Pharmacology & Therapeutics, 117(4), 910–919. https://doi.org/10.1002/cpt.3540
Castor EDC (2025). Automated evidence generation for regulatory-grade real-world data. https://www.castoredc.com/insight-briefs/automated-evidence-generation-regulatory-grade-real-world-data/ Last accessed 15JAN26
European Medicines Agency. (2025). Review of real-world data studies: Experience gained in conducting real-world data studies and providing real-world evidence to support EMA regulatory decision making since September 2021 (Infosheet). from https://www.ema.europa.eu/en/documents/other/infosheet-ema-review-real-world-data-studies-september-2021-february-2025_en.pdf Last accessed 15JAN26
Purpura, C. A., Garry, E. M., Honig, N., Case, A., & Rassen, J. A. (2022). The role of real-world evidence in FDA-approved new drug and biologics license applications. Clinical Pharmacology & Therapeutics, 111(1), 135–144. https://doi.org/10.1002/cpt.2474
U.S. Food and Drug Administration. (2018). Framework for FDA’s real-world evidence program. https://www.fda.gov/media/120060/download Last accessed 15JAN26
U.S. Food and Drug Administration. (2024). Real-world data: Assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological products (Guidance for industry). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-assessing-electronic-health-records-and-medical-claims-data-support-regulatory-decision Last accessed 15JAN26
U.S. Food and Drug Administration. (2025). Advancing real-world evidence program. https://www.fda.gov/drugs/development-resources/advancing-real-world-evidence-program Last accessed 15JAN26
